Curis Inc said it had been stopped from enrolling any new patients in an early stage trial of its experimental cancer drug following the death of a patient who had liver failure. Curis’s shares fell 10 percent in premarket trading after the U.S. Food and Drug Administration placed a partial hold on the trial. The company said the FDA was seeking additional data on patients treated with the drug, CUDC-427.
Help employers find you! Check out all the jobs and post your resume.
